Financial Data and Key Metrics Changes - Cintas achieved record revenues of $2.84 billion in Q3 2026, representing an 8.9% increase year-over-year, with organic growth at 8.2% [3][4] - Operating income rose to $659.9 million, an 8.2% increase over the prior year, with diluted EPS of $1.24, up 9.7% year-over-year [4][12] - Gross margin as a percentage of revenue was 51%, a 40 basis point increase from the previous year [3][12] Business Line Data and Key Metrics Changes - Organic growth by business segment included 7.3% for Uniform Rental Facility Services, 14.6% for First Aid and Safety Services, 10% for Fire Protection Services, and 3.1% for Uniform Direct Sale [7][8] - Gross margin percentages were 50.3% for Uniform Rental Facility Services, 58.1% for First Aid and Safety Services, 50.5% for Fire Protection Services, and 41.4% for Uniform Direct Sale [8][9] Market Data and Key Metrics Changes - The customer base remains resilient, with retention rates at record levels and pricing consistent with historical levels [10][11] - The addressable market is large, with solutions essential for businesses of all sizes, particularly in healthcare, hospitality, education, and government sectors [10][11] Company Strategy and Development Direction - Cintas is focused on strategic investments in technology, capacity, talent, and sales capabilities to drive growth and margin progression [18] - The company is excited about the acquisition of UniFirst, which is expected to close in the second half of calendar 2026, enhancing its ability to serve customers [5][11] Management's Comments on Operating Environment and Future Outlook - Management noted the current macro environment is complex but believes their value proposition continues to resonate with customers [10][33] - The company anticipates continued strong cash flow and maintains flexibility for capital deployment, including potential share buybacks post-UniFirst acquisition [14][66] Other Important Information - Selling and administrative expenses as a percentage of revenue increased to 27.8%, but were effectively flat year-over-year when adjusted for a one-time gain from the previous year [12][14] - The company expects adjusted diluted EPS for fiscal 2026 to be in the range of $4.86-$4.90, reflecting a growth rate of 10.5%-11.4% [5][14] Q&A Session Summary Question: How much of the EPS related to the UniFirst transaction was incurred in Q3 versus expected in Q4? - Management indicated that the estimated impact of $0.03-$0.04 EPS related to UniFirst was expected in Q4, with any Q3 costs being immaterial [23][24] Question: What are the energy costs as a percentage of revenue in the quarter? - Energy costs were 1.7%, flat year-over-year, with management noting that only 60% of energy costs relate to fuel for vehicles [27][28] Question: Can you provide an update on customer purchasing behaviors in the current macro environment? - Management reported that the customer base has been resilient, with no significant changes in purchasing behaviors [32][33] Question: What are the expectations for CapEx as a percentage of revenue post-UniFirst acquisition? - Management expects to maintain strong cash flow and does not anticipate significant changes in capital allocation priorities post-acquisition [41][42] Question: How are you managing the business leading up to the UniFirst acquisition? - Management stated that there are no changes in their approach, continuing to invest for the long term [108][109]

Financial Data and Key Metrics Changes - Consolidated net revenues increased by 6% year-over-year, driven by strong performance in the motorhome RV segment, which offset declines in towable RV and marine segments [18][19] - Gross profit improved due to top-line growth and SG&A reductions, resulting in a 51% increase in operating income from the second quarter of fiscal 2025, leading to adjusted EPS of $0.27, a 42% increase compared to last year [18][19] Business Line Data and Key Metrics Changes - Towable RV segment net revenues declined by 9%, primarily due to a shift towards lower price point models and lower unit volume, with an operating income margin of 4.2%, down 20 basis points from the prior year [19][20] - Motorhome RV segment net revenues increased by 29%, with volume momentum across Newmar, Winnebago, and Grand Design brands, resulting in an operating income margin improvement of 270 basis points year-over-year to 2.4% in Q2 [20] - Marine segment net revenues decreased by 3%, primarily due to lower unit volume and product mix, with an operating income margin of 3.7%, down 300 basis points from last year [21] Market Data and Key Metrics Changes - Retail activity in the second quarter reflected a seasonally slower period, with lower comps than the same period last year, impacted by adverse weather events in key regions [10][11] - The RV Industry Association forecasts modest industry shipment growth of approximately 2% year-over-year for calendar 2026, with expectations of improvement in the back half of the year as retail demand stabilizes [11][12] Company Strategy and Development Direction - The company is focused on introducing meaningful new products, particularly in the motorhome RV segment, emphasizing technological differentiation and affordability [6][10] - Strategic focus on driving share in higher value segments such as Class A diesel and Class C diesel reflects the company's aim to enhance retail dollar and profit reach [6][10] - The company is committed to deleveraging its balance sheet and strengthening cash flow to position itself for future capital allocation priorities [10][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a challenging market environment but expresses confidence in the company's ability to protect profitability and manage costs effectively [5][10] - The company is monitoring geopolitical developments closely, particularly in the Middle East, and their potential impact on consumer demand and input costs [28] - Despite current market conditions, management believes in the long-term fundamentals of the outdoor recreation sector, which contributes significantly to the economy [26][28] Other Important Information - The company has made significant improvements in workplace safety and reduced its Scope 1 and Scope 2 emissions by about 15% compared to the 2020 baseline [18] - The acquisition of Lithionics has strengthened the company's competitive differentiation by providing advanced battery power solutions, which are increasingly vital for future growth [9][100] Q&A Session Summary Question: Inventory management and future expectations - Management anticipates a combination of seasonal retail momentum and cautious inventory management to improve inventory turns to the target of 2 turns by the end of the calendar year [30][31] Question: Impact of geopolitical events on consumer demand - Management has not observed any direct adverse effects from the conflict in the Middle East on consumer demand yet but is monitoring the situation closely [32] Question: Weather impacts on retail trends - Management noted that weather events in January and February affected retail activity, but March has shown a healthier retail environment compared to the previous months [36][38] Question: Margin improvement initiatives in motorhomes - Management expects ongoing improvements in margins for the Winnebago motorhome business, with positive impacts anticipated in the coming quarters [86] Question: Update on electric vehicle strategy - The company is not currently pursuing an all-electric motorhome platform but is focused on electrification of house power through its Lithionics brand [55][56] Question: Tax refunds and consumer behavior - Management noted that tax refunds appear to be elevated this year, which could positively impact consumer spending, but it is too early to determine the material impact [94][96]

Financial Data and Key Metrics Changes - Total revenue increased by 20% year-over-year to $1.8 billion, with management solutions revenue growing by 23% to $1.4 billion, primarily driven by product penetration and price realization [15][4] - Adjusted operating income increased by 22% year-over-year, with operating income margin at 43.8% and adjusted operating income margin rising by approximately 80 basis points to 47.7% [15][4] - Diluted earnings per share rose by 9% to $1.56, while adjusted diluted earnings per share increased by 15% to $1.71 [16] - Free cash flow generation increased by 27% year-over-year, with operating cash flows nearly reaching $2 billion year-to-date [17] Business Line Data and Key Metrics Changes - PEO and insurance solutions revenue grew by 9% to $398 million, driven by strong growth in the number of average PEO worksite employees and an increase in PEO insurance revenues [15] - The ASO and PEO worksite employee growth continued to outpace the industry, reflecting the company's value in navigating regulatory complexity [7][9] - The company reported robust revenue growth in retirement, ASO, and PEO, indicating a long secular growth runway for these businesses [7] Market Data and Key Metrics Changes - The company noted stable workforce levels among clients, supported by solutions that help manage costs and source talent in a tight labor market [4] - The demand for comprehensive advisory and benefit solutions remains strong, differentiating the company from tech-only providers [7] Company Strategy and Development Direction - The integration of Paycor is progressing well, with expectations to exceed fiscal 2026 synergy targets [9] - The company is embedding AI into its workflows to enhance productivity and client outcomes, with over 500 AI-powered capabilities now in use [10][11] - The strategic focus is on leveraging proprietary payroll data and regulatory expertise to maintain a competitive advantage while embedding AI responsibly [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning for success in the AI era of HCM, emphasizing strong business fundamentals and a commitment to returning capital to shareholders [19] - The company anticipates fourth-quarter growth of approximately 12% with an adjusted operating margin of 41%-42% [18] - Management highlighted the importance of trust and ethical operations, noting recognition as one of the world's most ethical companies [13] Other Important Information - The company has a strong financial position with cash, restricted cash, and total corporate investments of $1.8 billion, alongside total borrowings of approximately $5 billion [16] - The company returned $463 million to shareholders this quarter and over $1.5 billion year-to-date through cash dividends and share buybacks [17] Q&A Session Summary Question: Can you elaborate on the level of organic growth in the third quarter and expectations for the fourth quarter? - Management indicated that organic growth has improved sequentially, with expectations for a similar performance in Q4, driven by easier comparisons and stronger operating performance [24][25] Question: How is the competitive environment and new sales performance during the core selling season? - Management described the competitive environment as stable, with strong performance in Q3, particularly in PEO and Paycor bookings, and noted the addition of sales headcount to capture demand [33][34] Question: Can you discuss the drivers behind the strong PEO insurance growth? - Management attributed the growth to strong underlying performance, record worksite employee retention, and successful annual enrollment, with a focus on providing affordable benefits to small business clients [51][52] Question: What are the expectations for revenue and expense synergies from the Paycor acquisition? - Management noted that expense synergies are expected to be in the $100 million range, with revenue synergies contributing significantly to growth, particularly through cross-selling opportunities [75][74]

Financial Data and Key Metrics Changes - Total revenue increased by 20% year-over-year to $1.8 billion, with management solutions revenue growing by 23% to $1.4 billion, driven by product penetration and price realization [15][4] - Adjusted operating income increased by 22% year-over-year, with operating income margin at 43.8% and adjusted operating income margin rising approximately 80 basis points to 47.7% [15][4] - Diluted earnings per share rose by 9% to $1.56, while adjusted diluted earnings per share increased by 15% to $1.71 [16] - Free cash flow generation increased by 27% year-over-year, with operating cash flows nearly reaching $2 billion year-to-date [17] Business Line Data and Key Metrics Changes - PEO and insurance solutions revenue increased by 9% to $398 million, primarily driven by strong growth in the number of average PEO worksite employees [15] - ASO and PEO worksite employee growth continues to outpace the industry, reflecting the company's value in navigating regulatory complexity [7] - The company reported robust revenue growth in retirement, ASO, and PEO, highlighting the durability of its business model [7] Market Data and Key Metrics Changes - The company operates in a highly regulated industry, providing a competitive advantage through compliance depth and advisory expertise [5] - Demand for comprehensive advisory and benefit solutions remains strong, differentiating the company from tech-only providers [7] Company Strategy and Development Direction - The company is focused on embedding AI into its workflows to enhance productivity and client outcomes, with over 500 AI-powered capabilities now in use [10] - The integration of Paycor is progressing well, with expectations to exceed fiscal 2026 synergy targets [9] - The company aims to leverage its proprietary payroll data and regulatory expertise to maintain a competitive moat while embedding AI responsibly [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning for success in the AI era of HCM, emphasizing strong business fundamentals and operating margins [19] - The company anticipates fourth-quarter growth of approximately 12% with an adjusted operating margin of 41%-42% [18] - Management highlighted the importance of trust and ethical operations, as evidenced by recognition as one of the world's most ethical companies [13] Other Important Information - The company returned $463 million to shareholders this quarter and over $1.5 billion year-to-date through cash dividends and share buybacks [17] - The company was recognized for its commitment to corporate responsibility and community support [13] Q&A Session Summary Question: Can you elaborate on the level of organic growth in the third quarter and its implications for the fourth quarter? - Management noted that organic growth has improved sequentially, with expectations for a similar performance in Q4, driven by easier comparisons and stronger operating performance [24][25] Question: How is the competitive environment and new sales performance? - Management described the competitive environment as stable, with strong performance in Q3, particularly in PEO and Paycor bookings, and noted the addition of sales headcount to capture demand [33][34] Question: Can you discuss the drivers behind the strong PEO insurance growth? - Management attributed the growth to strong underlying performance, record retention rates, and successful annual enrollment, with a focus on providing affordable benefits to small businesses [51][52] Question: What are the expectations for revenue and expense synergies from the Paycor acquisition? - Management indicated that expense synergies are expected to be in the $100 million range, with revenue synergies contributing positively to growth, particularly through cross-selling opportunities [75][76]

Financial Data and Key Metrics Changes - Total revenue increased by 20% year-over-year to $1.8 billion, with management solutions revenue growing by 23% to $1.4 billion, primarily driven by product penetration and price realization [12][3] - Adjusted operating income increased by 22% year-over-year, with operating income margin at 43.8% and adjusted operating income margin rising approximately 80 basis points to 47.7% [12][14] - Diluted earnings per share rose by 9% to $1.56, while adjusted diluted earnings per share increased by 15% to $1.71 [14] Business Line Data and Key Metrics Changes - PEO and insurance solutions revenue grew by 9% to $398 million, driven by strong growth in the number of average PEO worksite employees and an increase in PEO insurance revenues [12] - Interest on funds held for clients increased by 33% to $57 million, largely due to the addition of Paycor balances [12] - The ASO and PEO worksite employee growth continues to outpace the industry, reflecting the company's value in navigating regulatory complexity [5][7] Market Data and Key Metrics Changes - The company reported high single-digit worksite employee growth in the PEO business, driven by robust demand and record retention rates [5][48] - Medical enrollment across the PEO space was up high single digits, near double digits during the annual enrollment period [50] - The competitive environment remains stable, with double-digit bookings growth in both PEO and Paycor segments [29][30] Company Strategy and Development Direction - The integration of Paycor is progressing well, with expectations to exceed fiscal 2026 synergy targets [7] - The company is embedding AI into its workflows to enhance productivity and client outcomes, with over 500 AI-powered capabilities now in use [8][10] - The focus on advisory and compliance solutions differentiates the company from tech-only providers, reinforcing its competitive advantage [4][5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning for sustained growth in the AI era of HCM, emphasizing strong business fundamentals and cash flow generation [17] - The company anticipates fourth-quarter growth of approximately 12% with an adjusted operating margin of 41%-42% [16] - Management highlighted the importance of trust and ethical operations, noting recognition as one of the world's most ethical companies [10] Other Important Information - The company returned $463 million to shareholders this quarter and over $1.5 billion year-to-date through cash dividends and share buybacks [15] - The company has a strong financial position with cash and investments totaling $1.8 billion and total borrowings of approximately $5 billion [14] Q&A Session Summary Question: Can you elaborate on the level of organic growth in Q3 and expectations for Q4? - Management noted that organic growth improved sequentially, with expectations for a similar performance in Q4, driven by easier comparisons and stronger operating performance [20][22] Question: How is the competitive environment and new sales performance? - The competitive environment remains stable, with double-digit bookings growth in both PEO and Paycor segments, and the company is adding headcount in the enterprise space [29][30] Question: Can you discuss the drivers behind the strong PEO insurance performance? - Management attributed the strong performance to high demand for PEO services, record retention rates, and successful annual enrollment [48][50] Question: How does the company view the impact of AI on the advisory side of the business? - Management believes that the advisory work is complex and cannot be easily replaced by AI, emphasizing the importance of human expertise in compliance and regulatory matters [37][39]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported a net income of $1.23 billion and diluted earnings per share of $25.48, reflecting significant appreciation in treasury and treasury-related assets [3][11] - The company ended the year with $2.31 billion in total treasury and treasury-related assets and $1.93 billion in shareholders' equity, indicating strong financial positioning [11][12] Business Line Data and Key Metrics Changes - The clinical platform, particularly Allocetra, has shown clinically meaningful and statistically significant results, with a favorable safety profile, advancing towards late-stage development in osteoarthritis and other inflammatory indications [9][15] - The treasury strategy is designed to capture value from the emerging prediction markets economy, which is expected to grow significantly [4][12] Market Data and Key Metrics Changes - The prediction markets ecosystem is evolving, with increasing trading volumes and institutional engagement, positioning the company to capture early structural momentum [4][12] - The RAIN token, as a primary digital treasury reserve asset, is expected to benefit from the growth of decentralized prediction markets, enhancing long-term shareholder value [13][14] Company Strategy and Development Direction - The company is focused on a dual-engine model that integrates clinical development with a treasury strategy aligned with the growth of prediction markets [3][10] - The strategic partnership with the Rain Foundation allows the company to acquire RAIN tokens at a fixed price, enhancing its capital structure and growth potential [5][7] Management's Comments on Operating Environment and Future Outlook - Management believes that the current results are not isolated but represent the beginning of a broader shift towards institutional adoption of prediction markets [24] - The company aims to continue scaling its treasury strategy and advancing clinical programs, with a focus on capturing value across both scientific innovation and financial infrastructure [17][28] Other Important Information - The company announced a $21 million debt financing agreement to fund clinical development and acquire additional RAIN tokens at a discount [7][8] - A share repurchase program was approved to acquire up to $20 million of outstanding ordinary shares, indicating confidence in the company's value [8] Q&A Session Summary Question: Why is Enlivex posting large profits for 2025 despite a downturn in crypto? - Management attributed the profits to the bullish market for prediction markets, specifically the RAIN token, which increased in value [20] Question: How to explain the market cap discount to treasury valuation? - Management noted that the overall crypto market has been out of favor, leading to net asset value discounts, but expects this to improve as the prediction market ecosystem grows [21] Question: Does this change how clinical-stage companies can be financed? - Management indicated that the funding landscape has changed, with earlier-stage biotech companies facing challenges, but Enlivex's model allows for self-funding through treasury asset appreciation [22][23] Question: Is this a one-off outcome or the beginning of a broader shift? - Management sees this as the beginning of a broader shift towards public companies providing exposure to prediction markets [24] Question: How should investors view Enlivex after these results? - Management believes investors will now pay more attention to both sides of the dual model strategy following the earnings report [26] Question: What are the key drivers for scaling this model? - Management identified the growth of the prediction markets ecosystem and the advancement of the clinical program as key drivers for scalability [27]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported a net income of $1.23 billion and diluted earnings per share of $25.48, reflecting a significant appreciation in treasury and treasury-related assets [3][11] - The total treasury and treasury-related assets reached $2.31 billion, with shareholders' equity at $1.93 billion, indicating strong financial positioning [11][12] Business Line Data and Key Metrics Changes - The company operates a dual-engine model combining clinical development with a treasury strategy focused on prediction markets, which is expected to drive long-term value [3][10] - The clinical platform, particularly Allocetra, has shown clinically meaningful results and is advancing towards late-stage development in osteoarthritis, with FDA clearance for a phase IIb trial [9][15] Market Data and Key Metrics Changes - The prediction markets ecosystem is experiencing structural momentum, with increasing trading volumes and institutional engagement, positioning the company to capture early opportunities [12][14] - The RAIN token, as a primary digital treasury reserve asset, is expected to benefit from the growth of decentralized prediction markets, enhancing long-term shareholder value [13][14] Company Strategy and Development Direction - The company aims to establish itself as a leader in a new category of public companies that integrate scientific innovation with financial infrastructure [10][17] - A strategic partnership with the Rain Foundation allows the company to acquire RAIN tokens at a fixed price, enhancing its capital structure and growth potential [5][8] Management's Comments on Operating Environment and Future Outlook - Management believes the current results are indicative of a broader shift towards institutional adoption of prediction markets, with expectations for continued growth in this sector [24][27] - The company is focused on scaling its treasury strategy and advancing clinical programs, with a commitment to leading the convergence of biology and finance [17][28] Other Important Information - The company announced a $21 million debt financing agreement to support clinical development and acquire additional RAIN tokens [7][8] - A share repurchase program was approved to acquire up to $20 million of outstanding shares, reflecting confidence in the company's value [8] Q&A Session Summary Question: Why is Enlivex posting large profits for 2025 despite a downturn in crypto? - Management attributed the profits to the bullish market for prediction markets, specifically the RAIN token, which increased in value [20] Question: How to explain the market cap discount to treasury valuation? - Management noted that the overall crypto market is out of favor, leading to net asset value discounts, but expects this to improve as the prediction market ecosystem grows [21] Question: Does this change how clinical-stage companies can be financed? - Management indicated that the funding landscape has shifted, with earlier-stage biotech companies facing challenges, but Enlivex's model allows for self-funding through treasury asset appreciation [22][23] Question: Is this a one-off outcome or the beginning of a broader shift? - Management sees this as the beginning of a broader shift towards public companies providing exposure to prediction markets [24] Question: How should investors think about Enlivex after these results? - Management believes investors will now pay more attention to the dual model strategy following the earnings report [26] Question: What are the key drivers for scaling this model? - Management identified the growth of the prediction markets ecosystem and the success of the clinical program as key drivers for scalability [27]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported a net income of $1.23 billion and diluted earnings per share of $25.48, reflecting a significant appreciation in treasury and treasury-related assets [3][11] - The total treasury and treasury-related assets reached $2.31 billion, with shareholders' equity at $1.93 billion, indicating strong financial positioning [11][12] Business Line Data and Key Metrics Changes - The company's dual-engine model integrates clinical development with a treasury strategy focused on prediction markets, which is expected to drive long-term value [3][10] - The clinical platform, particularly Allocetra, has shown statistically significant results and a favorable safety profile, with a clear pathway toward late-stage development in osteoarthritis [9][16] Market Data and Key Metrics Changes - The prediction markets ecosystem is experiencing structural momentum, with increasing trading volumes and institutional engagement, positioning the company to capture early opportunities [12][18] - The RAIN token, as a primary digital treasury reserve asset, is expected to benefit from the growing decentralized prediction markets, enhancing long-term shareholder value [13][15] Company Strategy and Development Direction - The company aims to establish itself as a leader in a new category of public companies that combine scientific innovation with emerging financial infrastructure [10][18] - A strategic partnership with the Rain Foundation allows the company to acquire RAIN tokens at a fixed price, enhancing its capital structure and growth potential [5][8] Management's Comments on Operating Environment and Future Outlook - Management believes that the prediction markets will continue to evolve into a core layer of global financial infrastructure, validating the company's treasury strategy [4][12] - The company is optimistic about the scalability of its dual-engine model, driven by the growth of both prediction markets and its clinical programs [30][31] Other Important Information - The company announced a $21 million debt financing agreement to fund clinical development and acquire additional RAIN tokens at a discount [6][7] - A share repurchase program was approved to acquire up to $20 million of outstanding shares, reflecting confidence in the company's long-term value [8] Q&A Session Summary Question: Why is Enlivex posting large profits for 2025 despite a downturn in crypto? - The company's exposure to prediction markets, particularly the RAIN token, has led to significant valuation increases, contrasting with broader crypto market trends [20][22] Question: How to explain the market cap discount to treasury valuation? - The current market sentiment towards crypto has led to net asset value discounts, but there is hope for recovery as the prediction market ecosystem grows [23] Question: Does this change how clinical-stage companies can be financed? - The funding landscape for early-stage biotech has become more challenging, but Enlivex's model allows for self-funding through treasury asset appreciation, mitigating dilution concerns [24][25] Question: Is this a one-off outcome for prediction markets in public company earnings? - Management views this as the beginning of a broader shift towards integrating prediction markets into public company structures [26] Question: How should investors view Enlivex after these results? - Investors are likely to reassess the company's value proposition, recognizing the potential of its dual model strategy [29] Question: What are the key drivers for scaling this model? - The scalability will depend on the growth of the prediction markets ecosystem and the success of the clinical programs, with several milestones planned for the next two years [30]

Financial Data and Key Metrics Changes - In 2025, total revenue reached RMB 2.37 billion, representing a 135% year-over-year growth [4][15] - Product sales amounted to RMB 1.44 billion, up 43% from the previous year [4][15] - The company achieved a net profit of RMB 644 million, marking its first profitable year [4][15] - Cash position at the end of 2025 was RMB 2.8 billion, supporting ongoing R&D investments [5][16] - R&D expenses were RMB 950 million, reflecting a 16.9% year-over-year growth [16] Business Line Data and Key Metrics Changes - Orelabrutinib received regulatory approval for multiple indications, significantly expanding its commercial space [10][11] - Tafasitamab was approved for DLBCL in mainland China, enhancing the company's oncology portfolio [10][20] - Mesutoclax is being developed for four indications, with ongoing clinical trials showing promising results [11][25] Market Data and Key Metrics Changes - The global partnership strategy yielded a total business development deal value exceeding $2.5 billion in 2025 [5][18] - The company is focusing on expanding its presence in both domestic and international markets, with significant breakthroughs in globalization [18][19] Company Strategy and Development Direction - The company aims to become a global pharmaceutical leader by focusing on oncology and autoimmune diseases [4] - A diversified product portfolio is being developed, transitioning into multiple commercial and late-stage assets [15][17] - The company is investing in innovative platforms such as ADC and molecular glue technologies to enhance its R&D capabilities [16][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over 35% growth in drug sales for 2026, driven by Orelabrutinib and new product launches [17][54] - The company anticipates continued profitability and sustainable growth, supported by a strong pipeline and business development opportunities [55][62] Other Important Information - The company has over 10 phase III registrational studies ongoing, with multiple major products expected to receive regulatory approvals in the next two to three years [14][19] - The first ADC product, ICP-B794, is in the dose escalation stage of phase I trials, showing promising preliminary results [40][46] Q&A Session Summary Question: What is the sales potential for Orelabrutinib in 2026? - Management expects Orelabrutinib to continue growing over 30% due to deeper penetration in CLL and MCL, along with broader hospital coverage [51][53] Question: What is the development plan for ICP-488 overseas? - The company plans to expand indications after the phase III readout and is open to partnerships for global development [57][59] Question: What is the forecast for R&D expenses in 2026? - R&D expenses are expected to grow by around 20% in 2026, focusing on late-stage clinical studies and innovation platforms [61][62] Question: How will ICP-488 position itself against competitors in the psoriasis market? - The company believes its TYK2 inhibitor has a broader potential compared to oral IL-23 therapies, targeting multiple autoimmune diseases [73][75] Question: What are the inclusion criteria for the Orelabrutinib plus Mesutoclax data? - The combination therapy shows promising results in unfit older patients, providing a good treatment option for this population [78]

Financial Data and Key Metrics Changes - Revenue in Q3 increased by over 24% year-over-year, reaching $379 million compared to $305 million in the prior year quarter [12][13] - Adjusted EBITDA grew by 15% year-over-year, totaling $85 million with an Adjusted EBITDA margin of 22.3% [5][13] - GAAP earnings per share were $0.92, up from $0.79 in the prior year, with adjusted earnings at $0.98 per share, marking the sixth consecutive quarter of year-over-year growth in adjusted EPS [12][13] Business Line Data and Key Metrics Changes - Building Products segment net sales grew 36% year-over-year to $224 million, driven by higher volumes and contributions from acquisitions [18] - Consumer Products segment net sales increased by 11% year-over-year to $155 million, supported by improved volumes and higher average selling prices [20] - Adjusted EBITDA for Building Products was $59 million with a margin of 26.3%, while Consumer Products achieved $35 million in adjusted EBITDA with a margin of 22.9% [18][20] Market Data and Key Metrics Changes - The demand in end markets is steady, with expectations for growth as market conditions improve [10][11] - The company is not over-indexed to any specific vertical or industry, allowing for diversified growth opportunities [30] Company Strategy and Development Direction - The company is leveraging the Worthington Business System (WBS) focusing on innovation, transformation, and M&A to maximize growth [6][8] - Recent acquisitions, such as LSI, are expected to enhance the company's position in engineered building systems and contribute to future growth [8][74] - The company is investing in workforce development through career accelerator programs to build a skilled labor pool for the future [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to grow market share and capitalize on strengths as market conditions improve [5][11] - The company is focused on maintaining a conservative leverage ratio and ample liquidity, with a net debt to trailing Adjusted EBITDA ratio of approximately 1x [17] Other Important Information - The company returned $9 million to shareholders through dividends and share repurchases during the quarter [15] - Free cash flow for the trailing 12 months was $164 million, reflecting a 95% conversion rate relative to adjusted net earnings [16] Q&A Session Summary Question: Can you talk about volume versus price in organic revenue growth? - Management indicated that both volume and pricing contributed to organic growth, with Building Products up 16% and Consumer Products up 11% [25][27] Question: Can you provide color on organic growth expectations for Q4? - Management refrained from providing specific guidance but noted that trends are expected to continue [30] Question: How is the tank business in data centers performing? - Management highlighted significant growth in the ASME cooling tanks business, expecting it to triple this year and continue growing for several years [36][38] Question: What is the status of the LSI acquisition? - The acquisition is meeting expectations, with early integration efforts showing promise [74][75] Question: How are tariffs impacting the business? - Management believes they are net beneficiaries of tariffs, which provide a competitive advantage as a domestic manufacturer [80][81]